Developer docs
API playgroundTry for free, no card

Search company profiles

Acadia

Full company profile

uuid000587a

Namestring
Acadia
Legal namestring
Acadia Pharmaceuticals Inc.
Websiteurl
acadia.com
Company typeenum
Public
Founded yearint
2006
Descriptiontext

Acadia Pharmaceuticals Inc. is a publicly traded biopharmaceutical company (NASDAQ: ACHC) headquartered in San Diego, California, that develops and commercializes prescription therapies for central nervous system (CNS) disorders and rare neurological diseases characterized by high unmet medical need. The company markets two FDA-approved products: NUPLAZID (pimavanserin), approved for Parkinson's Disease Psychosis (PDP), and DAYBUE (trofinetide), the first and only approved treatment for Rett syndrome. A new powder formulation, DAYBUE STIX, received FDA approval in December 2025 and entered broad availability in April 2026. Acadia's strategic focus is conditions where no approved therapies previously existed.

Acadia's portfolio is built on proprietary small-molecule pharmacology. Pimavanserin is a selective serotonin inverse agonist (SSIA) targeting the 5-HT2A receptor and was the first therapy approved specifically for PDP. Trofinetide is a synthetic analog of the C-terminal tripeptide of insulin-like growth factor 1 (IGF-1), with a powder formulation now extending the franchise. The clinical pipeline includes remlifanserin, a Phase 2 candidate for Alzheimer's Disease Psychosis, with topline data expected between August and October 2026. The pipeline also includes programs targeting CNS indications beyond the current two approved products, providing optionality on future revenue streams.

Acadia operates a sales-led specialty pharmaceutical model, reaching neurologists, psychiatrists, and movement disorder specialists through medical affairs outreach and distributing through specialty pharmacies and direct healthcare provider channels. FY2025 GAAP total revenues reached $1.07 billion (12% YoY growth), with FY2026 guidance of $1.22 to $1.28 billion. The company is profitable, reporting $274 million of Q4 2025 net income and $391 million of full-year 2025 net income. Distribution is currently concentrated in the United States, Canada, and Israel, with CHMP having recommended EU approval of DAYBUE in June 2026, signaling near-term geographic expansion into the United Kingdom, Germany, France, Italy, Spain, and Switzerland.

Short descriptiontext

Acadia Pharmaceuticals Inc. is a publicly traded biopharmaceutical company developing and commercializing FDA-approved therapies for CNS and rare neurological disorders, including NUPLAZID for Parkinson's Disease Psychosis and DAYBUE for Rett syndrome.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersMontclair, United States
HQ citystring
Montclair
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CNS therapeutics, rare disease treatments, neurological disorder drugs, prescription pharmaceuticals, Parkinson's disease psychosis
Industry4 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Acadia generates revenue primarily through the sale of prescription pharmaceutical products. The company reported full year 2025 GAAP total revenues of $1.07 billion, marking the first time the company surpassed $1 billion in annual revenue. Revenue is driven by NUPLAZID net sales ($760 to $790 million guidance for 2026) and DAYBUE net sales ($460 to $490 million guidance for 2026).

businesswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Marketing or Sales, Personnel, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1NUPLAZID
Description

FDA-approved treatment for Parkinson's Disease Psychosis.

acadia.com
+1 more record
Core offering1 text field

Acadia Pharmaceuticals Inc. develops and commercializes FDA-approved prescription pharmaceutical treatments for central nervous system (CNS) disorders and rare neurological diseases. Its two marketed products are NUPLAZID (pimavanserin) for Parkinson's Disease Psychosis and DAYBUE (trofinetide) for Rett syndrome, with the latter also available in a powder formulation (DAYBUE STIX). The company also maintains a clinical pipeline that includes a Phase 2 candidate (remlifanserin) for Alzheimer's Disease Psychosis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • First company to surpass $1 billion in annual revenue for Rett Syndrome and Parkinson's Disease Psychosis treatments.
+3 more records
Product overview1 text field

Acadia Pharmaceuticals Inc. is a pharmaceutical company focused on developing medicines for CNS disorders and rare diseases. The company markets two FDA-approved products: NUPLAZID (pimavanserin) for Parkinson's Disease Psychosis and DAYBUE (trofinetide) for Rett syndrome (the first and only approved treatment for this rare neurodevelopmental disorder). DAYBUE is available in both oral solution and powder (STIX) formulations. The pipeline includes remlifanserin in Phase 2 for Alzheimer's disease psychosis, with results expected in late 2026. The company reported $1.07 billion in full-year 2025 GAAP total revenues, surpassing $1 billion for the first time, and issued 2026 guidance of $1.22 to $1.28 billion total revenues.

Product and service3 records
1NUPLAZID (pimavanserin)
CategorySpecialty Pharmaceutical
Description

FDA-approved prescription treatment for Parkinson's Disease Psychosis (PDP), a non-motor symptom impacting approximately half of people with Parkinson's over the course of their disease. Indicated for patients with Parkinson's Disease Psychosis.

2DAYBUE (trofinetide)
CategorySpecialty Pharmaceutical
Description

FDA-approved prescription treatment for Rett syndrome, a rare genetic neurological and developmental disorder affecting movement, coordination, and communication. Available in oral solution formulation for adults and pediatric patients two years and older.

3DAYBUE STIX (trofinetide powder formulation)
CategorySpecialty Pharmaceutical
Description

FDA-approved powder formulation of trofinetide for treating Rett syndrome in patients two years and older. Bioequivalent to the original DAYBUE oral solution with greater flexibility in administration. Over 80% satisfaction reported among early users during limited launch.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1CHMP (European Medicines Agency)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-26
Description

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommended approval for DAYBUE (trofinetide) in the European Union. Acadia is pursuing regulatory approval in Europe for the treatment of Rett syndrome.

acadia.com
2Jonathan M. Poole
Strategic tierMinorTypeOthersAnnounced on2026-03-03
Description

Jonathan M. Poole was appointed to Acadia Pharmaceuticals' Board of Directors as a strategic governance update.

acadia.com
3Co-promotion Partners
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Acadia collaborates with partners for co-promotion of products developed and marketed jointly. The company mentions partners for specific products or services including co-promotion arrangements.

acadia.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialty CNS pharmaceutical company that developed and commercialized Caplyta (lumateperone) for schizophrenia and bipolar depression, mirroring Acadia's model of a focused CNS/psychiatry franchise with a single high-value specialty product promoted through specialty channels.

TypeDirect peer
Description

Specialty CNS-focused pharma with a portfolio that includes products for Parkinson's disease (Apokyn), ADHD (Qelbree), and epilepsy — directly comparable to Acadia's CNS specialty commercial model and movement-disorder focus.

TypeDirect peer
Description

CNS specialty pharma commercializing Auvelity for major depressive disorder and other neurology assets — comparable in size, specialty distribution model, and CNS-focused GTM motion to Acadia.

TypeDirect peer
Description

CNS-focused biopharma commercializing Zurzuvae for postpartum depression — similar specialty pharma profile with first-in-class CNS approvals, narrow product portfolios, and direct neurology/psychiatry HCP engagement.

TypeDirect peer
Description

Specialty pharma with a CNS franchise (Xywav for narcolepsy) and rare disease focus (Epidiolex) — comparable to Acadia in commercial scale, specialty distribution, and dual CNS/rare disease focus.

TypeDirect peer
Description

CNS specialty pharma commercializing Ingrezza (valbenazine) for tardive dyskinesia and other movement-disorder therapies — directly comparable movement-disorder and CNS focus with similar specialty-channel commercialization.

TypeBroad incumbent
Description

Global Danish-headquartered CNS specialty pharmaceutical company with a broader neurology/psychiatry portfolio than Acadia, but overlapping in CNS commercial channels and HCP targeting.

TypeBroad incumbent
Description

Global biopharmaceutical company with a significant neurology and rare disease franchise (Vimpat, Keppra, Briviact, Rystiggo) — comparable CNS/neurology footprint but with broader therapeutic breadth and scale than Acadia.

TypeBroad incumbent
Description

Large generic/specialty pharma with a substantial CNS franchise (Austedo for Huntington's/tardive dyskinesia, Ajovy, Copaxone) — directly relevant to the movement-disorder neurology space while operating at much greater scale.

TypeBroad incumbent
Description

Global pharma with a major CNS franchise including Abilify (aripiprazole) and the long-acting Abilify Asimtufii, plus CNS digital therapies — directly relevant to Acadia's psychiatry/neurology specialty positioning but at significantly greater size and breadth.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Acadia

Specialty Pharmaceuticalsacadia.com

Acadia Pharmaceuticals Inc. is a publicly traded biopharmaceutical company developing and commercializing FDA-approved therapies for CNS and rare neurological disorders, including NUPLAZID for Parkinson's Disease Psychosis and DAYBUE for Rett syndrome.

What Acadia does

Acadia Pharmaceuticals Inc. is a publicly traded biopharmaceutical company (NASDAQ: ACHC) headquartered in San Diego, California, that develops and commercializes prescription therapies for central nervous system (CNS) disorders and rare neurological diseases characterized by high unmet medical need. The company markets two FDA-approved products: NUPLAZID (pimavanserin), approved for Parkinson's Disease Psychosis (PDP), and DAYBUE (trofinetide), the first and only approved treatment for Rett syndrome. A new powder formulation, DAYBUE STIX, received FDA approval in December 2025 and entered broad availability in April 2026. Acadia's strategic focus is conditions where no approved therapies previously existed.

Acadia's portfolio is built on proprietary small-molecule pharmacology. Pimavanserin is a selective serotonin inverse agonist (SSIA) targeting the 5-HT2A receptor and was the first therapy approved specifically for PDP. Trofinetide is a synthetic analog of the C-terminal tripeptide of insulin-like growth factor 1 (IGF-1), with a powder formulation now extending the franchise. The clinical pipeline includes remlifanserin, a Phase 2 candidate for Alzheimer's Disease Psychosis, with topline data expected between August and October 2026. The pipeline also includes programs targeting CNS indications beyond the current two approved products, providing optionality on future revenue streams.

Acadia operates a sales-led specialty pharmaceutical model, reaching neurologists, psychiatrists, and movement disorder specialists through medical affairs outreach and distributing through specialty pharmacies and direct healthcare provider channels. FY2025 GAAP total revenues reached $1.07 billion (12% YoY growth), with FY2026 guidance of $1.22 to $1.28 billion. The company is profitable, reporting $274 million of Q4 2025 net income and $391 million of full-year 2025 net income. Distribution is currently concentrated in the United States, Canada, and Israel, with CHMP having recommended EU approval of DAYBUE in June 2026, signaling near-term geographic expansion into the United Kingdom, Germany, France, Italy, Spain, and Switzerland.

Acadia firmographics

Firmographics
Name
Acadia
Legal name
Acadia Pharmaceuticals Inc.
Website
https://acadia.com
Company type
Public
Founded year
2006
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Acadia Pharmaceuticals Inc. is a publicly traded biopharmaceutical company developing and commercializing FDA-approved therapies for CNS and rare neurological disorders, including NUPLAZID for Parkinson's Disease Psychosis and DAYBUE for Rett syndrome.
Ownership category
akta.pro rank

Acadia industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • CNS therapeutics
  • Rare disease treatments
  • Neurological disorder drugs
  • Prescription pharmaceuticals
  • Parkinson's disease psychosis

Where Acadia is headquartered

Location

Headquarters

HQ city
Montclair
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Acadia business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Marketing or Sales, Personnel, Supply Chain

Revenue model

  1. Pharmaceutical Product Sales: Acadia generates revenue primarily through the sale of prescription pharmaceutical products. The company reported full year 2025 GAAP total revenues of $1.07 billion, marking the first time the company surpassed $1 billion in annual revenue. Revenue is driven by NUPLAZID net sales ($760 to $790 million guidance for 2026) and DAYBUE net sales ($460 to $490 million guidance for 2026).

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Acadia product offering

Product offering

Core offering

Acadia Pharmaceuticals Inc. develops and commercializes FDA-approved prescription pharmaceutical treatments for central nervous system (CNS) disorders and rare neurological diseases. Its two marketed products are NUPLAZID (pimavanserin) for Parkinson's Disease Psychosis and DAYBUE (trofinetide) for Rett syndrome, with the latter also available in a powder formulation (DAYBUE STIX). The company also maintains a clinical pipeline that includes a Phase 2 candidate (remlifanserin) for Alzheimer's Disease Psychosis.

Product overview

Acadia Pharmaceuticals Inc. is a pharmaceutical company focused on developing medicines for CNS disorders and rare diseases. The company markets two FDA-approved products: NUPLAZID (pimavanserin) for Parkinson's Disease Psychosis and DAYBUE (trofinetide) for Rett syndrome (the first and only approved treatment for this rare neurodevelopmental disorder). DAYBUE is available in both oral solution and powder (STIX) formulations. The pipeline includes remlifanserin in Phase 2 for Alzheimer's disease psychosis, with results expected in late 2026. The company reported $1.07 billion in full-year 2025 GAAP total revenues, surpassing $1 billion for the first time, and issued 2026 guidance of $1.22 to $1.28 billion total revenues.

Differentiator

Problem solved

Functional benefit

Brands

  • NUPLAZID: FDA-approved treatment for Parkinson's Disease Psychosis.
  • DAYBUE

Products and services

  • NUPLAZID (pimavanserin) FDA-approved prescription treatment for Parkinson's Disease Psychosis (PDP), a non-motor symptom impacting approximately half of people with Parkinson's over the course of their disease. Indicated for patients with Parkinson's Disease Psychosis.
  • DAYBUE (trofinetide) FDA-approved prescription treatment for Rett syndrome, a rare genetic neurological and developmental disorder affecting movement, coordination, and communication. Available in oral solution formulation for adults and pediatric patients two years and older.
  • DAYBUE STIX (trofinetide powder formulation) FDA-approved powder formulation of trofinetide for treating Rett syndrome in patients two years and older. Bioequivalent to the original DAYBUE oral solution with greater flexibility in administration. Over 80% satisfaction reported among early users during limited launch.

Quantifiable outcome

  • First company to surpass $1 billion in annual revenue for Rett Syndrome and Parkinson's Disease Psychosis treatments.
  • +3 more outcomes

Companies that use Acadia

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Acadia technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Acadia partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • CHMP (European Medicines Agency)coreStrategic or Co-development Partner · 26 June 2026The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommended approval for DAYBUE (trofinetide) in the European Union. Acadia is pursuing regulatory approval in Europe for the treatment of Rett syndrome.
  • Jonathan M. PooleminorOthers · 3 March 2026Jonathan M. Poole was appointed to Acadia Pharmaceuticals' Board of Directors as a strategic governance update.
  • Co-promotion PartnersminorChannel Partner/ Reseller/ DistributorAcadia collaborates with partners for co-promotion of products developed and marketed jointly. The company mentions partners for specific products or services including co-promotion arrangements.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Acadia competitors and assessment

Company assessment

Direct peers

  • Intra-Cellular Therapies: Specialty CNS pharmaceutical company that developed and commercialized Caplyta (lumateperone) for schizophrenia and bipolar depression, mirroring Acadia's model of a focused CNS/psychiatry franchise with a single high-value specialty product promoted through specialty channels.
  • Supernus Pharmaceuticals: Specialty CNS-focused pharma with a portfolio that includes products for Parkinson's disease (Apokyn), ADHD (Qelbree), and epilepsy — directly comparable to Acadia's CNS specialty commercial model and movement-disorder focus.
  • Axsome Therapeutics: CNS specialty pharma commercializing Auvelity for major depressive disorder and other neurology assets — comparable in size, specialty distribution model, and CNS-focused GTM motion to Acadia.
  • Sage Therapeutics: CNS-focused biopharma commercializing Zurzuvae for postpartum depression — similar specialty pharma profile with first-in-class CNS approvals, narrow product portfolios, and direct neurology/psychiatry HCP engagement.
  • Jazz Pharmaceuticals: Specialty pharma with a CNS franchise (Xywav for narcolepsy) and rare disease focus (Epidiolex) — comparable to Acadia in commercial scale, specialty distribution, and dual CNS/rare disease focus.
  • Neurocrine Biosciences: CNS specialty pharma commercializing Ingrezza (valbenazine) for tardive dyskinesia and other movement-disorder therapies — directly comparable movement-disorder and CNS focus with similar specialty-channel commercialization.

Broad incumbents

  • Lundbeck: Global Danish-headquartered CNS specialty pharmaceutical company with a broader neurology/psychiatry portfolio than Acadia, but overlapping in CNS commercial channels and HCP targeting.
  • UCB: Global biopharmaceutical company with a significant neurology and rare disease franchise (Vimpat, Keppra, Briviact, Rystiggo) — comparable CNS/neurology footprint but with broader therapeutic breadth and scale than Acadia.
  • Teva Pharmaceutical Industries: Large generic/specialty pharma with a substantial CNS franchise (Austedo for Huntington's/tardive dyskinesia, Ajovy, Copaxone) — directly relevant to the movement-disorder neurology space while operating at much greater scale.
  • Otsuka Pharmaceutical: Global pharma with a major CNS franchise including Abilify (aripiprazole) and the long-acting Abilify Asimtufii, plus CNS digital therapies — directly relevant to Acadia's psychiatry/neurology specialty positioning but at significantly greater size and breadth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Acadia social profiles

Digital presence

Acadia compliance and trust

Trust signal

Compliance3 records

Acadia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Acadia leadership team

Management profile

Number of profiles

Profiles4 records

Acadia funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Acadia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acadia

What does Acadia do?

Acadia Pharmaceuticals Inc. develops and commercializes FDA-approved prescription pharmaceutical treatments for central nervous system (CNS) disorders and rare neurological diseases. Its two marketed products are NUPLAZID (pimavanserin) for Parkinson's Disease Psychosis and DAYBUE (trofinetide) for Rett syndrome, with the latter also available in a powder formulation (DAYBUE STIX). The company also maintains a clinical pipeline that includes a Phase 2 candidate (remlifanserin) for Alzheimer's Disease Psychosis.

Is Acadia a public or private company?

Acadia is a public company. It is classified as public and is currently operating.

When was Acadia founded?

Acadia was founded in 2006. It employs 1,001 to 5,000 people.

Where is Acadia based?

Acadia is headquartered in Montclair, United States, in the North America region.

How does Acadia make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Acadia's main competitors?

Direct peers on record are Intra-Cellular Therapies, Supernus Pharmaceuticals, Axsome Therapeutics, Sage Therapeutics, Jazz Pharmaceuticals and Neurocrine Biosciences. Broad incumbents are Lundbeck, UCB, Teva Pharmaceutical Industries and Otsuka Pharmaceutical.

Does Acadia have an API?

No public API is recorded for Acadia.

What industry is Acadia in?

Acadia's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceAcadia Pharmaceuticals Appoints Carl Segerstrom as Chief People OfficerAcadia Pharmaceuticals appointed Carl Segerstrom as Chief People Officer, effective July 6. He brings over 25 years of global HR leadership, including a 17-year career at Merck. He will lead Acadia's people and culture strategy as it scales.MorningstarAcadia Pharmaceuticals Appoints Carl Segerstrom as Chief People OfficerAcadia Pharmaceuticals appointed Carl Segerstrom as Chief People Officer, effective July 6. He brings over 25 years of HR leadership, including a 17-year career at Merck, and will lead global people and culture strategy. He will join the executive leadership team.Business Wire BlogAcadia Pharmaceuticals Appoints Carl Segerstrom as Chief People OfficerAcadia Pharmaceuticals appointed Carl Segerstrom as Chief People Officer, effective July 6. He brings over 25 years of global HR leadership, including a 17-year career at Merck. He will lead Acadia's people and culture strategy as the company scales.BioSpaceDAYBU® (trofinetide) Recommended for Approval in the European Union by CHMPThe European Medicines Agency's CHMP recommended marketing authorization for DAYBU (trofinetide) to treat neurobehavioral symptoms of Rett syndrome in adults and children aged five and older. The recommendation is based on Phase 3 LAVENDER study results showing significant improvements. The European Commission is expected to issue a final decision in the coming months.AETOSWireDAYBU® (trofinetide) Recommended for Approval in the European Union by CHMPThe EMA's CHMP recommended approval of DAYBU (trofinetide) for neurobehavioral symptoms of Rett syndrome in adults and children aged five and older. The recommendation is based on the Phase 3 LAVENDER study, which showed significant improvements. The European Commission is expected to issue a final decision in the coming months.MorningstarDAYBU® (trofinetide) Recommended for Approval in the European Union by CHMPThe European Medicines Agency's CHMP recommended approval of DAYBU (trofinetide) for neurobehavioral symptoms of Rett syndrome in adults and children aged five and older. The recommendation is based on Phase 3 LAVENDER study results showing significant improvements. The European Commission is expected to issue a final decision in the coming months.Business Wire BlogAcadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial GuidanceAcadia Pharmaceuticals reported Q1 2026 revenues of $268 million, up 10% year-over-year, with NUPLAZID sales of $167 million and DAYBUE sales of $101 million. The company reaffirmed its full-year 2026 guidance and expects Phase 2 topline results from its remlifanserin Alzheimer's psychosis study between August and October 2026.YahooAcadia (ACHC) Q1 2026 Earnings Call TranscriptAcadia Healthcare reported strong Q1 2026 financial results, with revenue at the high end of guidance and adjusted EBITDA of $144.2 million, exceeding the top end of guidance by $7.2 million. Revenue growth of 14% in acute inpatient psychiatric facilities was driven by a 6.2% increase in inpatient volumes, while the specialty team also delivered better-than-expected results despite challenges in Pennsylvania. Based on the solid quarterly performance, the company raised its full-year adjusted EBITDA guidance by $5 million at the midpoint.Business Wire BlogAcadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished CareerAcadia Pharmaceuticals announced the planned year-end retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, for personal reasons. She will remain as consultant through at least the end of 2026 to ensure continuity during the readout of the Phase 2 remlifanserin study in Alzheimer's disease psychosis. Acadia has initiated a search for a new R&D leader.BioSpaceAcadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual MeetingAcadia Pharmaceuticals will present multiple original data presentations at the 2026 AAN Annual Meeting in Chicago, covering its portfolio. The presentations include real-world data on DAYBUE for Rett syndrome, exploratory analyses of NUPLAZID for Parkinson's disease psychosis, and translational research on ACP-711 for essential tremor.